Newer Clinical Strategies for Combining Interferon and Cytotoxic Agents Against Solid Tumours and Hematological Malignancies

The role of interferons in the treatment of cancer continues to evolve. Despite limited single agent activity against solid tumours, interferons now appear to have an important role as modulators of the activity of a variety of cytotoxic drugs. Clinical benefits have been observed for combinations o...

Full description

Saved in:
Bibliographic Details
Main Author: Scott Wadler
Format: Article
Language:English
Published: Wiley 1994-01-01
Series:Canadian Journal of Infectious Diseases
Online Access:http://dx.doi.org/10.1155/1994/474259
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832545366973612032
author Scott Wadler
author_facet Scott Wadler
author_sort Scott Wadler
collection DOAJ
description The role of interferons in the treatment of cancer continues to evolve. Despite limited single agent activity against solid tumours, interferons now appear to have an important role as modulators of the activity of a variety of cytotoxic drugs. Clinical benefits have been observed for combinations of interferons and alkylating agents against low grade lymphomas, interferons and dacarbazine against malignant melanoma, and interferons and 5-fluorouracil against gastrointestinal and genitourinary malignancies. Further progress will depend on a grealer understanding of the biology of the interaction.
format Article
id doaj-art-50d5b4ab8826439aa78b28a3ffca2aa1
institution Kabale University
issn 1180-2332
language English
publishDate 1994-01-01
publisher Wiley
record_format Article
series Canadian Journal of Infectious Diseases
spelling doaj-art-50d5b4ab8826439aa78b28a3ffca2aa12025-02-03T07:26:01ZengWileyCanadian Journal of Infectious Diseases1180-23321994-01-015Suppl A17A22A10.1155/1994/474259Newer Clinical Strategies for Combining Interferon and Cytotoxic Agents Against Solid Tumours and Hematological MalignanciesScott Wadler0Albert Einstein Cancer Center and the Department of Oncology, Montefiore Medical Center, Bronx, New York, USAThe role of interferons in the treatment of cancer continues to evolve. Despite limited single agent activity against solid tumours, interferons now appear to have an important role as modulators of the activity of a variety of cytotoxic drugs. Clinical benefits have been observed for combinations of interferons and alkylating agents against low grade lymphomas, interferons and dacarbazine against malignant melanoma, and interferons and 5-fluorouracil against gastrointestinal and genitourinary malignancies. Further progress will depend on a grealer understanding of the biology of the interaction.http://dx.doi.org/10.1155/1994/474259
spellingShingle Scott Wadler
Newer Clinical Strategies for Combining Interferon and Cytotoxic Agents Against Solid Tumours and Hematological Malignancies
Canadian Journal of Infectious Diseases
title Newer Clinical Strategies for Combining Interferon and Cytotoxic Agents Against Solid Tumours and Hematological Malignancies
title_full Newer Clinical Strategies for Combining Interferon and Cytotoxic Agents Against Solid Tumours and Hematological Malignancies
title_fullStr Newer Clinical Strategies for Combining Interferon and Cytotoxic Agents Against Solid Tumours and Hematological Malignancies
title_full_unstemmed Newer Clinical Strategies for Combining Interferon and Cytotoxic Agents Against Solid Tumours and Hematological Malignancies
title_short Newer Clinical Strategies for Combining Interferon and Cytotoxic Agents Against Solid Tumours and Hematological Malignancies
title_sort newer clinical strategies for combining interferon and cytotoxic agents against solid tumours and hematological malignancies
url http://dx.doi.org/10.1155/1994/474259
work_keys_str_mv AT scottwadler newerclinicalstrategiesforcombininginterferonandcytotoxicagentsagainstsolidtumoursandhematologicalmalignancies